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Accelerating HPV Vaccine Compliance with the Usage of MyLVHN Patient Portal
KM Rarick, DO and M Saltz, MD
Department of Pediatrics, Lehigh Valley Health Network, Allentown, Pennsylvania

METHODS

INTRODUCTION
HPV vaccine compliance has been a topic of controversy within many pediatric
offices across the country. Majority of parents have concerns regarding
the efficacy, safety, cost, and reason for
vaccination; and in many cases there is not
enough time for physicians to effectively
educate them during well visits. When
baseline data was collected at one LVHN
office, it was found that the vaccination rates
collectively (50.7%) were below the national
average (girls: 63%, boys: 50%), which was
collected by the CDC.
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•	Patients 12 to 16 years of age who had previously declined the HPV vaccine were
considered eligible for this study.
•	Study took place at one LVHN pediatric office, which consisted of six pediatricians,
from October to November of 2016
•	The means of communication was set to use MyLVHN, which is a secure online
portal that allows patients/parents to communicate with their medical team.
•	Eligible patients were called to either verify their use of MyLVHN if already active,
or to facilitate activation over the phone.
•	Parents or guardians who accepted this means of communication were told
to expect a message in the next 1-2 weeks regarding the HPV vaccine. This
message included an informational video, CDC facts regarding the vaccine, and
other sites to do more research if inclined. Using a secure online communication
network would allow them to review and do their own research prior to making the
decision to vaccinate.

Of the 60 eligible patients aged
12-16 years of age, 26 of them
already had or were agreeable to
sign up for MyLVHN. At the end of
the study, 76.2% of the patients
received the HPV vaccine which
was a 25.5% increase in vaccine
compliance from baseline data
collected at this office.
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Figure 2: After the implementation of communication via MyLVHN prior to well visit,
vaccination rates increased to 76.2% for all eligible teens (16 of 21 patients).

CONCLUSION

Exclusion Criteria:
•	Any patient who started or completed the
HPV vaccination series or was older than
16 years of age.

Received vaccine
50.7%

RESULTS

The implementation of MyLVHN as a mode of communication to educate and inform
parents prior to well visits increased compliance to the HPV vaccine by 25.5% over the
eight week study period.
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Figure 1: Baseline data collected from same LVHN office for 4 weeks prior to the study found HPV vaccine
compliance at 50.7% for all teens (32 of 63 eligible patients) which was below the national average.

OBJECTIVES:
•	Increase the vaccination rates of the HPV vaccine during an 8 week
period at one LVHN pediatric office.
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